Gary K. Schwartz

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Editor’s Note: Inhibition of NF-κB–Dependent Signaling Enhances Sensitivity and Overcomes Resistance to BET Inhibition in Uveal Melanoma

  Cancer Research · 2026-06-15

• Skin health in oncology: evidence-based skin care for cancer patients

  The Oncologist · 2026-05-30

• The ATLAS study: A first-in-human phase 1/2 trial of [Ac-225]RTX-2358 in patients with relapsed or refractory soft tissue sarcoma.

  Journal of Clinical Oncology · 2026-05-28

• Atezolizumab for Alveolar Soft Part Sarcoma: A Clinical Trial Update

  Journal of Clinical Oncology · 2026-04-18

• Abstract 4859: A novel sarcoma tumoroid platform preserving the tumor microenvironment to guide personalized immunotherapy

  Cancer Research · 2026-04-03

• Tissue-Specific Expression of the EWSR1::FLI1 Fusion Protein Identifies col2a1a-Positive Cells as a Source of Ewing Sarcoma-like Tumors in Zebrafish

  International Journal of Molecular Sciences · 2026-03-30

• Oncostatin-M ligand-based CAR-T therapy displays robust anti-tumor activity against osteosarcoma

  BMC Medicine · 2026-03-17

• Performing Under Pressure: Maintenance of Donor Lung Pressure During Cabin Depressurization

  Interdisciplinary CardioVascular and Thoracic Surgery · 2026-01-07

• Table S8 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

  2025-12-11

• Table S4 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

  2025-12-11

• Supplementary Figures S1-S6 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

  2025-12-11

• Table S7 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

  2025-12-11

• Table S3 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

  2025-12-11

• Key Resources Table from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

  2025-12-11

• Table S6 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

  2025-12-11

• Table S2 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

  2025-12-11

• Table S5 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

  2025-12-11

• Table S1 from A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

  2025-12-11

• Supplementary Table S4 from Molecular Subtypes of Head and Neck Cancer in Patients of African Ancestry

  2025-11-25

• Supplementary Table S3 from Molecular Subtypes of Head and Neck Cancer in Patients of African Ancestry

  2025-11-25